Ani Pharmaceuticals (ANIP) Cash & Current Investments (2016 - 2025)
Ani Pharmaceuticals (ANIP) has disclosed Cash & Current Investments for 16 consecutive years, with $285.6 million as the latest value for Q4 2025.
- Quarterly Cash & Current Investments rose 97.12% to $285.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $285.6 million through Dec 2025, up 97.12% year-over-year, with the annual reading at $285.6 million for FY2025, 97.12% up from the prior year.
- Cash & Current Investments hit $285.6 million in Q4 2025 for Ani Pharmaceuticals, up from $262.6 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $285.6 million in Q4 2025 to a low of $15.3 million in Q3 2021.
- Historically, Cash & Current Investments has averaged $137.6 million across 5 years, with a median of $145.0 million in 2024.
- Biggest five-year swings in Cash & Current Investments: skyrocketed 718.38% in 2021 and later plummeted 49.45% in 2022.
- Year by year, Cash & Current Investments stood at $105.3 million in 2021, then tumbled by 49.45% to $53.2 million in 2022, then skyrocketed by 315.38% to $221.1 million in 2023, then plummeted by 34.47% to $144.9 million in 2024, then skyrocketed by 97.12% to $285.6 million in 2025.
- Business Quant data shows Cash & Current Investments for ANIP at $285.6 million in Q4 2025, $262.6 million in Q3 2025, and $217.8 million in Q2 2025.